CXCL11 and colorectal carcinoma: The enhanced intratumoral expression of CXCL11, as the presumably most potent CXCR3 agonist [34], turned out to correlate with the increased presence of CD4+ T helper (Th) cells and CD8+ cytotoxic T cells in human CRC lesions.